Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: a randomized controlled trial

BACKGROUND: Neoadjuvant chemotherapy (NACT) is the prime approach to the management of locally advanced breast cancer (LABC). Influenced by different factors such as pathologic tumor characteristics, hormone receptor status, HER2 and proliferation marker expressions, response to therapy cannot be ea...

Descripción completa

Detalles Bibliográficos
Autores principales: Firouzabadi, Dena, Dehghanian, Amirreza, Rezvani, Alireza, Mahmoudi, Laleh, Talei, Abdolrasoul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7798240/
https://www.ncbi.nlm.nih.gov/pubmed/33430808
http://dx.doi.org/10.1186/s12885-020-07652-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7798240/
https://www.ncbi.nlm.nih.gov/pubmed/33430808
http://dx.doi.org/10.1186/s12885-020-07652-0

Ejemplares similares